Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Open-label, Safety and Efficacy Study of XERMELO® (Telotristat Ethyl) Plus First-line Chemotherapy in Patients With Locally Advanced, Unresectable, Recurrent or Metastatic Biliary Tract Cancer (BTC)

NCT03790111 is registered in ClinicalTrials.gov with TerSera Therapeutics LLC as lead sponsor.

NCT NCT03790111
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03790111 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Open-label, Safety and Efficacy Study of XERMELO® (Telotristat Ethyl) Plus First-line Chemotherapy in Patients With Locally Advanced, Unresectable, Recurrent or Metastatic Biliary Tract Cancer (BTC)
Lead sponsor
TerSera Therapeutics LLC
Phase
Phase 2
Overall status
Terminated
Start date
March 13, 2019
Completion date
January 13, 2022
Enrollment
53 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer (btc)